… bortezomib and dexamethasone in patients with previously treated multiple myeloma:
three-year followup of CASTOR… Clin Lymphoma Myeloma Leuk. 2020;20:509-518. doi: 10.1016/j.…

… 737 patients with newly diagnosed multiple myeloma who were … At a median follow-up of
28.0 months, disease progression … patients with relapsed or refractory myeloma (the CASTOR …

… or the last known follow-up visit for censored patients, and ≥ … 47/57 cases were previously
treated with a bortezomib-based … in the pivotal CASTOR trial (16 months vs 7.8 months) [10]. …

… (mAb) daratumumab in intravenous form to treatment with … patients with newly diagnosed
multiple myeloma (NDMM). … therapy and on OS require longer follow-up. We know, for example, …

… Patients had censored data with follow-up ended if they had not had … treated multiple myeloma:
three-year follow-up of CASTOR. … of daratumumab in the treatment of multiple myeloma: a …

… follow-up for the entire cohort from the time of daratumumab … However, the included patients
in the CASTOR study were … of treatment as compared with our study that included patients …

… Median follow-up was calculated by the reverse Kaplan–Meier … the Castor trial comparing
daratumumab plus bortezomib plus dexamethasone versus bortezomib plus dexamethasone, …

… Subcutaneous daratumumab plus pomalidomide and dexamethasone has been … patients
with previously treated multiple myeloma. Additionally, the use of subcutaneous daratumumab …

… time from initiation of treatment (DPd or DVd) until death or last follow-up. DOR was defined
… Like our result, the indirect comparison of DPd from APOLLO study with DVd from CASTOR …

… daratumumab-dexa, both for patients with at least two prior … The PFS benefit in CASTOR
was seen in patients with prior … Median PFS was not reached after a median follow up of …